Novel pharmacological targets for the treatment of Parkinson's disease.

lenov's picture
TitleNovel pharmacological targets for the treatment of Parkinson's disease.
Publication TypeJournal Article
Year of Publication2006
AuthorsSchapira, AHV, Bezard, E, Brotchie, J, Calon, F, Collingridge, GL, Ferger, B, Hengerer, B, Hirsch, E, Jenner, P, Le Novère, N, Obeso, JA, Schwarzschild, MA, Spampinato, U, Davidai, G
JournalNat Rev Drug Discov
Volume5
Issue10
Pagination845-54
Date Published2006 Oct
ISSN1474-1776
KeywordsAdenosine A2 Receptor Antagonists, Antiparkinson Agents, Cholinergic Agents, Clinical Trials as Topic, Dopamine Agonists, Excitatory Amino Acid Antagonists, Humans, Monoamine Oxidase Inhibitors, Narcotic Antagonists, Parkinson Disease, Serotonin Antagonists, Serotonin Receptor Agonists
Abstract

<p>Dopamine deficiency, caused by the degeneration of nigrostriatal dopaminergic neurons, is the cause of the major clinical motor symptoms of Parkinson's disease. These symptoms can be treated successfully with a range of drugs that include levodopa, inhibitors of the enzymatic breakdown of levodopa and dopamine agonists delivered by oral, subcutaneous, transcutaneous, intravenous or intra-duodenal routes. However, Parkinson's disease involves degeneration of non-dopaminergic neurons and the treatment of the resulting predominantly non-motor features remains a challenge. This review describes the important recent advances that underlie the development of novel dopaminergic and non-dopaminergic drugs for Parkinson's disease, and also for the motor complications that arise from the use of existing therapies.</p>

DOI10.1038/nrd2087
Alternate JournalNat Rev Drug Discov
PubMed ID17016425